GeneDx Holdings (WGS) EBITDA Margin (2020 - 2026)

GeneDx Holdings has disclosed EBITDA Margin across 7 years of filings, most recently posting 62.17% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 5476.0% year-over-year to 62.17%; the TTM figure through Mar 2026 stood at 17.63% (down 613.0% YoY), while the FY2025 annual figure was 4.89%, up 1209.0% from the prior year.
• EBITDA Margin fell to 62.17% in Q1 2026, from 14.66% in the prior quarter.
• Over the last five years, EBITDA Margin for WGS reached as high as 10.44% in Q2 2025 and fell as low as 503.28% in Q4 2022.
• The 5-year median for EBITDA Margin is 44.15% (2023), against an average of 87.97%.
• Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 43375 bps — and 2023, when it jumped 45913 bps.
• A 5-year view of EBITDA Margin shows it stood at 503.28% in 2022, then surged by 91 bps to 44.15% in 2023, then surged by 113 bps to 5.59% in 2024, then sank by 362 bps to 14.66% in 2025, then tumbled by 324 bps to 62.17% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 62.17%, 14.66%, and 6.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.